

CIRM Funded Clinical Trials

A phase I/II study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) for the treatment of adults with COVID-19

Disease Area:	COVID-19
Investigator:	Xiaokui Zhang
Institution:	Celularity Inc
CIRM Grant:	CLIN2COVID19-11857
Award Value:	\$750,000
Trial Sponsor:	Celularity Inc
Trial Stage:	Phase 1/2
Trial Status:	Recruiting
Targeted Enrollment:	86
ClinicalTrials.gov ID:	NCT04365101



Xiaokui Zhang

Details:

This trial will use blood stem cells obtained from the placenta to generate natural killer (NK) cells, a type of white blood cell that is a vital part of the immune system, and administer them to patients with COVID-19. NK cells play an important role in defense against cancer and in fighting off viral infections. The goal is to administer these cells to locate the active sites of COVID-19 infection and destroy the virus-infected cells.

Design:

Phase I/II Study

Goal:

Safety, tolerability, and efficacy

Source URL: <https://www.cirm.ca.gov/clinical-trial/phase-iii-study-human-placental-hematopoietic-stem-cell-derived-natural-killer-cells>